Author/Authors :
Wu, Yun-Deng SpringPharma Tech Co. Ltd, People's Republic of China , Liu, Xiao-Hong SpringPharma Tech Co. Ltd, People's Republic of China , Xu, Jian SpringPharma Tech Co. Ltd, People's Republic of China , Zhang, Si-Han SpringPharma Tech Co. Ltd, People's Republic of China , Shen, Kun SpringPharma Tech Co. Ltd, People's Republic of China , Sun, Ling JiangSu Center for Safety Evaluation of Drugs, People's Republic of China , He, Yong-Mei SpringPharma Tech Co. Ltd, People's Republic of China , Ma, Yan SpringPharma Tech Co. Ltd, People's Republic of China , Zhang, Ai-Hua SpringPharma Tech Co. Ltd, People's Republic of China
Abstract :
The title compound, C22H24N2O7S·0.5C2H5OH·0.5H2O {systematic name: (S)-4-acetamido-2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]isoindoline-1,3-dione ethanol hemisolvate hemihydrate}, is a novel solvatomorph of apremilast (AP), which is an inhibitor of phosphodiesterase 4 (PDE4) and is indicated for the treatment of adult patients with active psoriatic arthritis. The asymmetric unit contains one molecule of AP and disordered molecules of ethanol and water, both with half occupancy. The dihedral angle between the planes of the phenyl ring and the isoindole ring is 67.9 (2)°. Extensive intra- and intermolecular hydrogen bonds help to stabilize the molecular conformation and sustain the crystal packing.
Keywords :
apremilast , PDE4 , psoriatic arthritis , crystal structure , solvatomorph , hydrogen bonding
